Gossamer Bio Inc. (NASDAQ:GOSS) saw a downside of -1.90% to close Tuesday at $1.03 after subtracting -$0.02 on the day. The 5-day average trading volume is 1,803,720 shares of the company’s common stock. It has gained $1.1400 in the past week and touched a new high 1 time within the past 5 days. An average of 1,772,710 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,587,076.
GOSS’s 1-month performance is -23.13% or -$0.3200 on its low of $0.9800 reached on 08/18/23. The company’s shares have touched a 52-week low of $0.91 and high of $15.19, with the stock’s rally to the 52-week high happening on 02/02/23. YTD, GOSS has lost -52.53% or -$1.1400 and has reached a new high 9 times. However, the current price is down -93.22% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
GOSS stock investors last saw insider trading activity on Jun 22.Aranda Richard (Chief Medical Officer) most recently sold 1,814 shares at $1.29 per share on Jun 22. This transaction cost the insider $2,340. EVP, Regulatory Affairs, Peterson Caryn, sold 7,564 shares at a price of $1.10 on Mar 16. Then, on Mar 16, Chief Medical Officer Aranda Richard sold 7,563 shares at a price of $1.10 per share. This transaction amounted to $8,304.
Valuation Metrics
GOSS stock has a beta of 1.21.
Gossamer Bio Inc.’s quick ratio for the period ended June 29 was 4.30, with the current ratio over the same period at 4.30. The firm’s gross profit as reported stood at $13.88 million against revenue of $218.59 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -32.87% to -$42.5 million, while revenue of -$49.17 million was -15.69% off the previous quarter. Analysts expected GOSS to announce -$0.49 per share in earnings in its latest quarter, but it posted -$0.45, representing a 8.20% surprise. EBITDA for the quarter stood at more than -$46.32 million. GOSS stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 244.55 million, with total debt at $219.16 million. Shareholders hold equity totaling $225.32 million.
Let’s look briefly at Gossamer Bio Inc. (GOSS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 29.91% to suggest the stock is trending oversold, with historical volatility in this time period at 41.66%.
The stock’s 5-day moving average is $1.0380, reflecting a -9.65% or -$0.1100 change from its current price. GOSS is currently trading -17.60% above its 20-day SMA, -22.56% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -11.97% and SMA200 by-90.28%.
Stochastic %K and %D was 11.06% and 8.83% and the average true range (ATR) pointed at 0.0940. The RSI (14) points at 35.77%, while the 14-day stochastic is at 11.11% with the period’s ATR at 0.1074. The stock’s 9-day MACD Oscillator is pointing at -0.0667 and -0.1279 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Gossamer Bio Inc. (NASDAQ: GOSS), UBS downgraded it to a Neutral rating. They previously had a Buy rating on the stock. Analysts offering their rating for GOSS stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate GOSS as a “sell,”, while 4 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 7 have offered a “buy” rating.
